Referanser

  1. Tranter R, O’Donovan C, Chandarana P, Kennedy S. Prevalence and outcome of partial remission in depression. J Psychiatry Neurosci 2002; 27: 241-7.
  2. Nierenberg AA, Keefe BR, Leslie VC, Alpert JE, Pava JA, Worthington JJ, 3rd, et al. Residual symptoms in depressed patients who respond acutely to fluoxetine. J Clin Psychiatry 1999; 60: 221-5.
  3. Spijker J, Bijl RV, de Graaf R, Nolen WA. Determinants of poor 1-year outcome of DSM-III-R major depression in the general population: results of the Netherlands Mental Health Survey and Incidence Study (NEMESIS). Acta Psychiatr Scand 2001; 103: 122-30.
  4. Moos RH, Cronkite RC. Symptom-based predictors of a 10-year chronic course of treated depression. J Nerv Ment Dis 1999; 187: 360-8.
  5. Nutt DJ, Demyttenaere K, Janka Z, Aarre T, Bourin M, Canonico PL, et al. The other face of depression, reduced positive affect: the role of catecholamines in causation and cure. J Psychopharmacol 2006; Oct 18
  6. Clayton AH, Pradko JF, Croft HA, Montano CB, Leadbetter RA, Bolden-Watson C, et al. Prevalence of sexual dysfunction among newer antidepressants. J Clin Psychiatry 2002; 63: 357-66.
  7. Rosen RC, Lane RM, Menza M. Effects of SSRIs on sexual function: a critical review. J Clin Psychopharmacol 1999; 19: 67-85.
  8. Rothschild AJ. Sexual side effects of antidepressants. J Clin Psychiatry 2000; 61 Suppl 11: 28-36.
  9. Segraves RT. Antidepressant-induced sexual dysfunction. J Clin Psychiatry 1998; 59. Suppl 4: 48-54.
  10. Sussman N, Ginsberg D. Weight gain associated with SSRIs. Prim Psychiatry 1998; 5: 28-39.
  11. Richelson E. Weight gain on SSRIs: a paradox? Prim Psychiatry 1998; 5: 40-1.
  12. Fava M, Rush AJ, Thase ME, Clayton A, Stahl SM, Pradko JF, et al. 15 years of clinical experience with bupropion HCl: from bupropion to bupropion SR to bupropion XL. Prim Care Companion J Clin Psychiatry 2005; 7: 106-13.
  13. Stahl SM, Pradko JF, Haight BR, Modell JG, Rockett CB, Learned-Coughlin S. A Review of the Neuropharmacology of Bupropion, a Dual Norepinephrine and Dopamine Reuptake Inhibitor. Prim Care Companion J Clin Psychiatry 2004; 6: 159-66.
  14. Stahl SM. Essential Psychopharmacology. Second edition ed. New York, NY: Cambridge University Press; 2000.
  15. Foote SL, Aston-Jones GS. Chapter 29. Pharmacology and physiology of central noradrenergic systems. In: Bloom FE, Kupfer DJ, editors. Psychopharmacology: the
    fourth generation of progress. New York: Raven Press Ltd; 1995. p. 335-45.
  16. Shelton RC, Tomarken AJ. Can recovery from depression be achieved? Psychiatry Serv 2001; 52: 1469-78.
  17. Stahl SM. Deconstructing psychiatric disorders, part 2: An emerging, neurobiologically based therapeutic strategy for the modern psychopharmacologist. J Clin Psychiatry 2003; 64: 1145-6.
  18. Weihs KL, Settle EC, Jr., Batey SR, Houser TL, Donahue RM, Ascher JA. Bupropion sustained release versus paroxetine for the treatment of depression in the elderly. J Clin Psychiatry 2000; 61: 196-202.
  19. Thase ME, Haight BR, Richard N, Rockett CB, Mitton M, Modell JG, et al. Remission rates following antidepressant therapy with bupropion or selective serotonin reuptake inhibitors: a meta-analysis of original data from 7 randomized controlled trials. J Clin Psychiatry 2005; 66: 974-81.
  20. Kavoussi RJ, Segraves RT, Hughes AR, Ascher JA, Johnston JA. Double-blind comparison of bupropion sustained release and sertraline in depressed outpatients. J Clin Psychiatry 1997; 58: 532-7.
  21. Kennedy SH, Fulton KA, Bagby RM, Greene AL, Cohen NL, Rafi-Tari S. Sexual function during bupropion or paroxetine treatment of major depressive disorder. Can J Psychiatry 2006; 51: 234-42.
  22. Chrzanowski W, Rousseau R, Gee M, Wightman D, Richard NE, Modell JG, Goodale EP. Efficacy and safety of bupropion extended release in elderly patients with major depressive disorder: European Neuropsychoparm, 2006, 16, Suppl 4, S315.
  23. Thase ME, Clayton AH, Chrzanowski W, Wunderlich H-P, Hewett K, Haight BR, et al. Bupropion extended release and venlafaxine extended release for the treatment of depression: European Psychiatry, 2006, 21, Suppl 1, S168.
  24. Thase ME, Clayton AH, Haight BR, Thompson AH, Modell JG, Johnston JA. A double-blind comparison between bupropion XL and venlafaxine XR: sexual functioning, antidepressant efficacy, and tolerability. J Clin Psychopharmacol 2006; 26: 482-8.
  25. Weihs KL, Houser TL, Batey SR, Ascher JA, Bolden-Watson C, Donahue RM, et al. Continuation phase treatment with bupropion SR effectively decreases the risk for relapse of depression. Biol Psychiatry 2002; 51: 753-61.
  26. Clayton AH. Extended-release bupropion: an antidepressant with a broad spectrum of therapeutic activity. Expert Opin Pharmacother 2007; 8: 457-66.
  27. Foley KF, DeSanty KP, Kast RE. Bupropion: pharmacology and therapeutic applications. Expert Rev Neurother 2006; 6: 1249-65.
  28. Felleskatalogtekst
  29. Wellbutrin Retard SPC
  30. Zisook S, Rush AJ, Haight BR, Clines DC, Rockett CB. Use of bupropion in combination with serotonin reuptake inhibitors. Biol Psychiatry. 2006:1;59(3):203-10.
  31. Trivedi MH et al. Medication Augmentation after the Failure of SSRIs for Depression. NEJM 2006; 354: 1243-1252.
  32. Jefferson JW. Strategies for switching antidepressants to achieve maximum efficacy. J Clin Psychiatry. 2008;69 Suppl E1:14-8.
  33. Legemiddelhåndboken T5,5 Depresjoner. Seponering.
  34. Kennedy SH, McCann SM, Masellis M, McIntyre RS, Raskin J, McKay G, Baker GB. Combining bupropion SR with venlafaxine, paroxetine, or fluoxetine: a preliminary report on pharmacokinetic, therapeutic, and sexual dysfunction effects. J Clin Psychiatry. 2002;63(3):181-6.
  35. Perlis RH, Fava M, Nierenberg AA, Pollack MH, Falk WE, Kienke AS, Rosenbaum JF.  Strategies for treatment of SSRI-associated sexual dysfunction: a survey of an academic psychopharmacology practice. Harv Rev Psychiatry.2002;10(2):109-14.
  36. PUBLIC ASSESSMENT REPORT (PAR) Evalueringsrapport på Wellbutrin XL fra nederlandske myndigheter 
^ Til toppen
Pasient med allergisk rhinitt

Publikumsinformasjon om depresjon

Relevant informasjon om behandling av depresjon beregnet for publikum.